I am a
Home I AM A Search Login

Papers of the Week

Papers: 5 Dec 2020 - 11 Dec 2020

Pharmacology/Drug Development


2020 Dec 09

Pain Manag

Galcanezumab for the prevention of migraine.


Frerichs LM, Friedman DI
Pain Manag. 2020 Dec 09.
PMID: 33291980.


Migraine is a common and disabling disorder affecting approximately 1.02 billion people worldwide. Calcitonin gene-related peptide (CGRP) has been identified as playing an important role in the pathophysiology of migraine and several migraine-specific therapies targeting the CGRP ligand or its receptor have been approved since 2018 for the acute and preventive treatment of migraine. This review focuses on the pharmacology, clinical efficacy and safety/tolerability of galcanezumab, an anti-CGRP monoclonal antibody approved for the prevention of migraine.